The existence of several MasR subtypes has been suggested based on the differential capacity of the two MasR blockers to fully inhibit some biological actions of Ang-(1–7) [and perhaps of Ang (1–5), see Figure 1] [39,70]; therefore, differently from ACE2 enzymatic inhibitors, MasR antagonists should be administered in combinations, in order to inhibit ACE2 hyperactivity.